| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1073858405285208 |
| P698 | PubMed publication ID | 16840707 |
| P50 | author | Frauke Zipp | Q21259942 |
| P2093 | author name string | Orhan Aktas | |
| Timour Prozorovski | |||
| P2860 | cites work | Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics | Q24564912 |
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment | Q33652471 | ||
| CD27-CD70 interactions regulate B-cell activation by T cells | Q33768464 | ||
| Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. | Q33774221 | ||
| Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
| Tolerance and autoimmunity | Q34167913 | ||
| Autoimmune diseases. | Q34325674 | ||
| New concepts in the immunopathogenesis of multiple sclerosis | Q34609924 | ||
| Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift | Q34956279 | ||
| Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis | Q35150296 | ||
| Lymphotoxin/light, lymphoid microenvironments and autoimmune disease | Q35219029 | ||
| Immunological aspects of demyelinating diseases | Q35319665 | ||
| Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions | Q35819856 | ||
| Na+ channel expression along axons in multiple sclerosis and its models | Q35921669 | ||
| An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis | Q36353675 | ||
| Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis | Q36368058 | ||
| The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. | Q36369234 | ||
| Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination | Q36376163 | ||
| Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease | Q36377160 | ||
| Multiple sclerosis: Fas signaling in oligodendrocyte cell death | Q36377383 | ||
| Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis | Q37174968 | ||
| Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein | Q37360410 | ||
| CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis | Q37696199 | ||
| Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5. | Q38363829 | ||
| Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. | Q40362975 | ||
| The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis | Q40546571 | ||
| Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells | Q40733996 | ||
| Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. | Q41279504 | ||
| T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms | Q41591469 | ||
| Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. | Q44795497 | ||
| Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis | Q45873858 | ||
| Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis | Q47810532 | ||
| BAFF augments certain Th1-associated inflammatory responses. | Q47810975 | ||
| Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis | Q48155188 | ||
| Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis | Q48160439 | ||
| FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier | Q48166557 | ||
| Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. | Q48325664 | ||
| Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice | Q48535553 | ||
| Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. | Q48894792 | ||
| Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. | Q49014751 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Upregulation and colocalization of p75 and Nav1.8 in Purkinje neurons in experimental autoimmune encephalomyelitis. | Q53731135 | ||
| TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. | Q54150165 | ||
| Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. | Q54653388 | ||
| Monoclonal antibody-mediated tumor regression by induction of apoptosis. | Q55059937 | ||
| Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) | Q57623656 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 305-316 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | The Neuroscientist | Q7753449 |
| P1476 | title | Death ligands and autoimmune demyelination | |
| P478 | volume | 12 |
| Q46701491 | Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis |
| Q82904254 | CD70: probably being a therapeutic target in human multiple sclerosis |
| Q37633504 | Creatine Enhances Mitochondrial-Mediated Oligodendrocyte Survival After Demyelinating Injury |
| Q46036987 | Dual role of Response gene to complement-32 in multiple sclerosis. |
| Q34496935 | Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes |
| Q48822291 | Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury |
| Q37071856 | Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. |
| Q38196321 | Guard of delinquency? A role of microglia in inflammatory neurodegenerative diseases of the CNS. |
| Q35206971 | Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination |
| Q35064198 | Krüppel-like factor 6 rendered rat Schwann cell more sensitive to apoptosis via upregulating FAS expression |
| Q37165162 | Maturation-dependent sensitivity of oligodendrocyte lineage cells to apoptosis: implications for normal development and disease |
| Q36832908 | Migraine in multiple sclerosis |
| Q34055604 | Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation |
| Q36991434 | New insights into adaptive immunity in chronic neuroinflammation |
| Q40500040 | RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. |
| Q37735773 | Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. |
| Q37119296 | TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1 |
Search more.